| 15.10. | ROCHE : la FDA homologue Tecentriq pour certains cancers du poumon |  |
| 15.10. | ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E.. |  |
| 15.10. | ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea.. | |
| 15.10. | PRESS RELEASE : US FDA approves Roche's Tecentriq -2- | |
| 15.10. | PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people.. | |
| 15.10. | GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients | |
| 15.10. | Investir dans la stabilité | |
| 15.10. | ROCHE : a conclu un accord avec PathAI | |
| 15.10. | Roche s'associe à Pathai dans l'imagerie médicale | |
| 15.10. | ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists | |
| 15.10. | ROCHE : autorisation à durée limitée de Gavreto par Swissmedic | |
| 15.10. | ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology.. | |
| 15.10. | PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig.. | |
| 14.10. | ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month | |
| 14.10. | ROCHE : examen prioritaire de la FDA pour REGEN-COV | |
| 14.10. | ROCHE : le Regen Cov jugé prioritaire aux USA en prévention de la Covid | |
| 14.10. | ROCHE : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatmen.. | |
| 14.10. | ROCHE : résultats encourageants dans les troubles NMOSD | |
| 14.10. | ROCHE : Scores Wins In Blood Cancer, Rare Nervous Disorder Therapeutic Areas | |
| 14.10. | ROCHE : Invitation to Roche's Virtual Event "Digitalization along the value chain" | |
| 14.10. | ROCHE : a reçu l'approbation de l'EMA pour Gazyvaro | |
| 14.10. | ROCHE : Rare Central Nervous System Disease Therapy Reduces Relapses In Patients | |
| 14.10. | Le Gazyvaro de Roche autorisé en Europe avec une perfusion plus courte | |
| 14.10. | ROCHE : Wins EU Nod For Shorter Gazyvaro Infusion Time in Follicular Lymphoma Patients | |
| 14.10. | ROCHE : New four-year data show Roche's ENSPRYNG significantly reduces debilitating relaps.. | |
| 14.10. | PRESS RELEASE : New four-year data show Roche's -2- | |
| 14.10. | PRESS RELEASE : New four-year data show Roche's ENSPRYNG significantly reduces debilitatin.. | |
| 14.10. | Roche Holding Ag Announces New Longer-Term Efficacy and Safety Data for ENSPRYNG | |
| 14.10. | ROCHE : New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduce.. | |
| 14.10. | ROCHE : Gazyvaro shorter 90-minute infusion time approved in Europe for people with previo.. | |
| 14.10. | PRESS RELEASE : Roche's Gazyvaro shorter 90-minute -2- | |
| 14.10. | PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe.. | |
| 14.10. | Roche’s Gazyvaro Shorter 90-Minute Infusion Time Gets Approval in Europe for People wit.. | |
| 13.10. | SYNAIRGEN : Appoints Chugai Pharma Executive as Chief Regulatory Officer | |
| 13.10. | ROCHE : données positives dans les scléroses en plaques | |
| 13.10. | REMINDER : Invitation to Roche's 3rd Quarter Sales 2021 Webinar | |
| 13.10. | ROCHE : Long-Term Data on Multiple Sclerosis Therapy Affirms Early, Ongoing Treatment Bene.. | |
| 13.10. | ROCHE : New Data up to 8-Years for Genentech's Ocrevus (ocrelizumab) Show Early and Ongoin.. | |
| 13.10. | ROCHE : Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoing treatm.. | |
| 13.10. | PRESS RELEASE : Data up to 8-years for Roche's -2- | |
| 13.10. | PRESS RELEASE : Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoin.. | |
| 13.10. | Roche Announces New Long-Term Data That Reinforce the Benefit of Early Initiation and O.. | |
| 12.10. | CombiGene Shares More Than Double on $328.5 Million Epilepsy Therapy Deal | |
| 12.10. | CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene t.. | |
| 12.10. | ROCHE : Japanese Unit Seeks Regulatory Nod For Additional COVID-19 Monoclonal Antibody Ind.. | |
| 11.10. | ROCHE : Chugai files for additional indications of Ronapreve for prophylaxis and treatment.. | |
| 11.10. | GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche... | |
| 11.10. | ROCHE : European Medicines Agency Reviews COVID-19 Antibody Cocktail Developed by Roche, R.. | |
| 11.10. | ROCHE : l'UE débute la procédure d'examen du médicament Ronapreve contre Covid-19 | |
| 11.10. | EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation | |
| 11.10. | REGENERON PHARMACEUTICALS : EU assesses Regeneron/Roche COVID-19 antibody cocktail for aut.. | |
| 11.10. | BÖRSE MADRID : Resultados a prueba de inflación y escasez |  |
| 11.10. | EN DIRECT DES MARCHES : Carrefour, Ipsen, CGG, Facebook, Apple, Lenovo, Adler, Idorsia... | |
| 08.10. | Alzheimer-medicijn Roche baanbrekend volgens FDA |  |
| 08.10. | ROCHE : says Alzheimer's therapy gets U.S. breakthrough designation | |
| 08.10. | ROCHE : statut de 'Breakthrough Therapy' dans Alzheimer | |
| 08.10. | Roche obtient le statut de percée thérapeutique aux USA pour gantenerumab | |
| 08.10. | ROCHE : Alzheimer Drug Gets US FDA's Breakthrough Therapy Designation | |
| 08.10. | ROCHE : says Alzheimer's antibody gets U.S. breakthrough designation | |
| 08.10. | ROCHE : anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designati.. | |
| 08.10. | GENENTECH : 's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy De.. | |
| 08.10. | Roche's Gantenerumab Gets FDA Breakthrough Therapy Designation for Alzheimer's Disease | |
| 07.10. | ROCHE : Philippine Drug Regulator OKs Roche-Regeneron's COVID-19 Antibody Cocktail | |
| 05.10. | ROCHE : nouvelles données pour la sclérose en plaques | |
| 05.10. | ROCHE : Highlights Long-Term Efficacy Of Neurological Disorder Drugs | |
| 05.10. | Roche promeut son Ocrevus et l'Enspryng sur le long terme | |
| 05.10. | GENENTECH : to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryn.. | |
| 05.10. | ROCHE : to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis.. | |
| 05.10. | PRESS RELEASE : Roche to present new data on -3- | |
| 05.10. | PRESS RELEASE : Roche to present new data on -2- | |
| 05.10. | PRESS RELEASE : Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in.. | |
| 04.10. | CHUGAI PHARMACEUTICAL : Receives Orphan Drug Designation for Hemlibra in Acquired Hemophil.. | |
| 04.10. | CHOROIDEREMIA PIPELINE : Industry Analysis, Drugs, Pipeline, Treatment and Key Companies b.. | |
| 02.10. | ROCHE : Malaysia in talks to procure Merck's COVID-19 pills | |
| 01.10. | Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
